Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

VIKING THERAPEUTICS Aktie

>Aktienkurs

30.46 EUR -1.1% (Tradegate)

Ask: 30.455 EUR / 500 Stück

Bid: 30.33 EUR / 600 Stück

Tagesumsatz: 2576 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -6,5%

1 Monat: -10,4%

3 Monate: +52,7%

6 Monate: +29,8%

1 Jahr: -32,3%

laufendes Jahr: -22,2%

>VIKING THERAPEUTICS Aktie

Name:

VIKING THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US92686J1060 / A12GD6

Symbol/ Ticker:

1VT (Frankfurt) / VKTX (NASDAQ)

Kürzel:

FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX

Index:

Webseite:

https://www.vikingtherape..

Profil:

Viking Therapeutics Inc. is a biopharmaceutical co..
>Volltext..

Marktkapitalisierung:

3582.63 Mio. EUR

Unternehmenswert:

2974.54 Mio. EUR

Umsatz:

EBITDA:

-233.72 Mio. EUR

Nettogewinn:

-202.21 Mio. EUR

Gewinn je Aktie:

-1.8 EUR

Schulden:

0.64 Mio. EUR

Liquide Mittel:

85.5 Mio. EUR

Operativer Cashflow:

-191.29 Mio. EUR

Bargeldquote:

27.41

Umsatzwachstum:

Gewinnwachstum:

-127.18%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

VIKING THERAPEUTICS, VIKING THERAPEUTIC

Letzte Datenerhebung:

17.12.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 113.04 Mio. St.

Frei handelbar: 97.17%

Leerverk. Aktien: 20.34%

Rückkaufquote: -0.06%

Mitarbeiter: 36

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 152.13%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 5.9

PEG-Ratio: -0.14

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -28.31%

Eigenkaprendite: -29.23%

>Peer Group

Es sind 599 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

16.12.25 - 19:48	1 Bold Prediction for Viking Therapeutics in 2026 (Fool)
	Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it....

16.12.25 - 01:00	Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
	Viking Therapeutics, Inc. (VKTX) closed at $36.15 in the latest trading session, marking a -2.51% move from the prior day....

08.12.25 - 17:30

Viking Therapeutics-Aktie: Was kommt 2026? (Sharedeals)

Kurz vor Jahresende nehmen wir die Aktie von Viking Therapeutics noch einmal unter die Lupe, denn das Unternehmen steht vor einem entscheidenden Jahr für seine Adipositas-Pipeline. Zwar sind keine Zulassungsentscheidungen zu erwarten, doch könnten zentrale Daten, strategische Weichenstellungen und mögliche Partnerschaften erheblichen Einfluss auf die Bewertung des Biotech-Unternehmens haben. Injektionspräparat VK2735: Reifephase rückt näher Das […] The post Viking Therapeutics-Aktie: Was kommt 2026? first appeared on sharedeals.de....

01.12.25 - 16:45	VKTX Stock Rises 34% in Three Months: Here′s What You Should Know (Zacks)
	Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments....

28.11.25 - 16:45	Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? (Zacks)
	According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...

25.11.25 - 22:09	Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
	SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Piper Sandler 37th......

21.11.25 - 19:00	Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue? (Zacks)
	Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

20.11.25 - 19:00	VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug (Zacks)
	Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program....

19.11.25 - 11:18	Viking Therapeutics gibt auf Jefferies-Konferenz Update zu Adipositas-Wirkstoff VK2735 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

19.11.25 - 08:57	Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 (PR Newswire)
	78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage......

18.11.25 - 20:48	5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? (Fool)
	One major biotech investor just walked away from Viking Therapeutics. Here's what the move may—and may not—mean for the company's clinical-stage future....

12.11.25 - 17:00	Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street′s Bullish Views? (Zacks)
	According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...

12.11.25 - 14:45	Viking Therapeutics Aktie: Biotech-Geheimtipp im Adipositasmarkt - Kursziel steigt auf 107 USD (Aktiencheck)
	Vancouver (www.aktiencheck.de) - Viking Therapeutics-Aktienanalyse von Canaccord Genuity: Die Analysten von Canaccord Genuity belassen die Einstufung für die Aktie von Viking Therapeutics, Inc. (ISIN: US92686J1060, WKN: A12GD6, Ticker-Symbol: 1VT, NASDAQ-Symbol: VKTX) auf "buy" und heben das Kursziel von 106 USD auf 107 USD an. [mehr]...

12.11.25 - 03:57	AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
	Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61. read more...

10.11.25 - 17:36	Nach Verkauf von Nvidia: Milliardär Stanley Druckenmiller investiert 93.100.000 Dollar in zwei Aktien (Wallstreet-Online)
	US-Milliardär Stanley Druckenmiller investiert Millionen von Dollar in zwei Aktien, nachdem er sich von Nvidia und Palantir getrennt hat.Jetzt den vollständigen Artikel lesen...

09.11.25 - 13:24	Is There a Future for Viking Therapeutics? (Fool)
	The weight loss drug company was counted out far too early in the summer, but investors are warming to it again....

06.11.25 - 13:09	Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 (PR Newswire)
	VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused......

05.11.25 - 11:48	Here′s Why Shares in Viking Therapeutics Shot Higher in October (Fool)
	Three factors took Viking's shares higher in the month....

04.11.25 - 22:09	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
	SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming......

03.11.25 - 17:06

Viking Therapeutics Could Be Pharma′s Next Big Buyout Target (24/7 Wall St.)

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma's Next Big Buyout Target The post Viking Therapeutics Could Be Pharma's Next Big Buyout Target appeared first on 24/7 Wall St.....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram